SEATTLE, Oct. 1, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG) and Fluidigm Corporation (Nasdaq:FLDM) have agreed to settle lawsuits filed by Fluidigm in the United States and Singapore. In the U.S. case, Fluidigm charged NanoString with false advertising, unfair competition, and unlawful trade practices based on a comparison study of NanoString’s Single Cell Gene Expression Assay on the nCounter® Analysis System with the Single Cell Gene Expression capabilities of Fluidigm’s BioMark™ HD system. The lawsuit in Singapore was based on the same study and contained similar allegations. NanoString denies the allegations in both lawsuits.
Help employers find you! Check out all the jobs and post your resume.
